CL2021001171A1 - Compuestos de anillo fusionado. - Google Patents

Compuestos de anillo fusionado.

Info

Publication number
CL2021001171A1
CL2021001171A1 CL2021001171A CL2021001171A CL2021001171A1 CL 2021001171 A1 CL2021001171 A1 CL 2021001171A1 CL 2021001171 A CL2021001171 A CL 2021001171A CL 2021001171 A CL2021001171 A CL 2021001171A CL 2021001171 A1 CL2021001171 A1 CL 2021001171A1
Authority
CL
Chile
Prior art keywords
fused ring
ring compounds
compounds
inhibition
administration
Prior art date
Application number
CL2021001171A
Other languages
English (en)
Inventor
Steven Do
Sushant Malhotra
Jack Terrett
Jianfeng Xin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021001171A1 publication Critical patent/CL2021001171A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Esta invención pertenece a compuestos de anillo fusionado de la Fórmula (I), como se indica más en detalle en la presente, que se usan para la inhibición de proteínas Ras, así como a composiciones que comprenden estos compuestos y métodos de tratamiento mediante su administración.
CL2021001171A 2018-11-09 2021-05-04 Compuestos de anillo fusionado. CL2021001171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018114788 2018-11-09

Publications (1)

Publication Number Publication Date
CL2021001171A1 true CL2021001171A1 (es) 2021-10-22

Family

ID=69232886

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001171A CL2021001171A1 (es) 2018-11-09 2021-05-04 Compuestos de anillo fusionado.
CL2022000698A CL2022000698A1 (es) 2018-11-09 2022-03-22 Compuestos de anillo fusionado. (divisional de solicitud 202101171)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000698A CL2022000698A1 (es) 2018-11-09 2022-03-22 Compuestos de anillo fusionado. (divisional de solicitud 202101171)

Country Status (22)

Country Link
US (2) US11236068B2 (es)
EP (1) EP3735299A2 (es)
JP (3) JP6941241B2 (es)
KR (2) KR102587544B1 (es)
CN (1) CN112105419B (es)
AR (1) AR117194A1 (es)
AU (3) AU2019377130B2 (es)
BR (1) BR112021008986A2 (es)
CA (1) CA3087089C (es)
CL (2) CL2021001171A1 (es)
CO (1) CO2021005987A2 (es)
CR (1) CR20210229A (es)
IL (2) IL311187A (es)
MA (1) MA51530A (es)
MX (1) MX2021005428A (es)
MY (1) MY196726A (es)
PE (1) PE20211504A1 (es)
PH (1) PH12021551065A1 (es)
SG (1) SG11202103298QA (es)
TW (2) TW202325703A (es)
UA (1) UA127930C2 (es)
WO (1) WO2020097537A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114437065A (zh) 2019-05-21 2022-05-06 益方生物科技(上海)股份有限公司 杂环化合物，其制备方法和用途
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021120045A1 (en) 2019-12-18 2021-06-24 InventisBio Co., Ltd. Heterocyclic compounds, preparation methods and uses thereof
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
WO2022035790A1 (en) * 2020-08-12 2022-02-17 Genentech, Inc. Synthesis of quinazoline compounds
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CN116323624A (zh) * 2020-09-30 2023-06-23 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
EP4240489A1 (en) * 2020-11-03 2023-09-13 Mirati Therapeutics, Inc. Kras g12d inhibitors
IL301293A (en) * 2020-11-13 2023-05-01 Genentech Inc Methods and compositions containing a KRASG12C inhibitor and a VEGF inhibitor for the treatment of solid tumors
US20220152029A1 (en) * 2020-11-13 2022-05-19 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
WO2022105855A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
TW202229285A (zh) * 2020-11-20 2022-08-01 大陸商北京加科思新藥研發有限公司 Kras g12d抑制劑
WO2022125427A1 (en) * 2020-12-08 2022-06-16 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors
CA3203080A1 (en) * 2020-12-22 2022-06-30 Hongqi Tian Preparation and application method of heterocyclic compound as kras inhibitor
CN113999226B (zh) * 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022171013A1 (zh) * 2021-02-09 2022-08-18 南京明德新药研发有限公司 四氢喹唑啉类化合物
WO2022173678A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
JP2024506329A (ja) * 2021-02-09 2024-02-13 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
WO2022177917A2 (en) * 2021-02-16 2022-08-25 Theras, Inc. Compositions and methods for inhibition of ras
CN117715915A (zh) * 2021-04-09 2024-03-15 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
WO2022221386A1 (en) * 2021-04-14 2022-10-20 Erasca, Inc. Selective kras inhibitors
EP4322954A1 (en) * 2021-04-16 2024-02-21 Merck Sharp & Dohme LLC Small molecule inhibitors of kras g12d mutant
AR125921A1 (es) * 2021-05-19 2023-08-23 Genentech Inc Terapia de combinación
WO2022247760A1 (zh) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
WO2022251496A1 (en) * 2021-05-26 2022-12-01 Cornell University Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer
CN117858878A (zh) * 2021-08-18 2024-04-09 北京加科思新药研发有限公司 N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023097194A2 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic compounds and methods of use
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
WO2023097227A1 (en) * 2021-11-24 2023-06-01 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
WO2023122662A1 (en) 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
TW202337466A (zh) * 2022-01-06 2023-10-01 美商德洛斯股份有限公司 用於抑制ｒａｓ之組合物及方法
TW202334155A (zh) * 2022-01-06 2023-09-01 美商德洛斯股份有限公司 用於抑制ｒａｓ之組合物及方法
WO2023150706A1 (en) * 2022-02-07 2023-08-10 Genentech, Inc. Solid forms of 1-((s)-4-((r)-7-(6-amino-4-methyl-3- (trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((s)-1- methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3- methylpiperazin-1-yl)prop-2-en-1-one
WO2023150653A1 (en) * 2022-02-07 2023-08-10 Genentech, Inc. Process for synthesis of quinazoline compounds
CN115043729A (zh) * 2022-07-04 2022-09-13 青岛大学 一种2,2’-二氟联芳基化合物的不对称合成方法
WO2024036270A1 (en) 2022-08-11 2024-02-15 Bristol-Myers Squibb Company Kras inhibitors
WO2024040131A1 (en) 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
CN117085515A (zh) * 2023-01-15 2023-11-21 安徽科博瑞环境科技有限公司 低表面能抗污染中空纤维膜的制备装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002557A1 (en) 1997-07-11 1999-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V Novel pharmaceutically active compounds interacting with gtp-binding proteins
JP5512665B2 (ja) 2008-06-20 2014-06-04 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
JP6399660B2 (ja) 2012-04-10 2018-10-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 癌治療用組成物および方法
CN106488910B (zh) 2013-10-10 2020-07-31 亚瑞克西斯制药公司 Kras g12c的抑制剂
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
WO2019099524A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
BR112020012329A2 (pt) 2017-12-19 2020-11-24 Merck Patent Gmbh antagonistas de tlr7/8 e usos dos mesmos
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物

Also Published As

Publication number Publication date
US20230089126A1 (en) 2023-03-23
CA3087089C (en) 2023-09-12
PH12021551065A1 (en) 2021-11-22
BR112021008986A2 (pt) 2021-08-10
US20210230142A9 (en) 2021-07-29
WO2020097537A2 (en) 2020-05-14
US11236068B2 (en) 2022-02-01
JP2024023189A (ja) 2024-02-21
SG11202103298QA (en) 2021-04-29
JP6941241B2 (ja) 2021-09-29
AR117194A1 (es) 2021-07-21
TWI784209B (zh) 2022-11-21
CR20210229A (es) 2021-06-30
CO2021005987A2 (es) 2021-05-20
WO2020097537A3 (en) 2020-06-11
JP2021512136A (ja) 2021-05-13
US20200181118A1 (en) 2020-06-11
CN112105419B (zh) 2024-03-29
TW202024060A (zh) 2020-07-01
CL2022000698A1 (es) 2022-10-21
TW202325703A (zh) 2023-07-01
MY196726A (en) 2023-05-03
PE20211504A1 (es) 2021-08-11
EP3735299A2 (en) 2020-11-11
KR102587544B1 (ko) 2023-10-11
AU2019377130B2 (en) 2022-03-17
AU2022201413B9 (en) 2024-03-21
KR20200119824A (ko) 2020-10-20
AU2019377130A1 (en) 2020-07-16
UA127930C2 (uk) 2024-02-14
AU2022201413A1 (en) 2022-03-24
CA3087089A1 (en) 2020-05-14
KR20230147742A (ko) 2023-10-23
IL282916A (en) 2021-06-30
CN112105419A (zh) 2020-12-18
JP7374960B2 (ja) 2023-11-07
MX2021005428A (es) 2021-06-15
JP2021169500A (ja) 2021-10-28
IL311187A (en) 2024-04-01
AU2024200904A1 (en) 2024-02-29
AU2022201413B2 (en) 2024-02-29
MA51530A (fr) 2021-04-21

Similar Documents

Publication Publication Date Title
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2021003036A2 (es) Compuestos de anillo fusionado
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2017002650A1 (es) Compuestos novedosos
CO2017011484A2 (es) Inhibidores de bromodominio
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2020001686A1 (es) Compuestos inhibidores del blanco mecanístico de rapamicina (mtor).
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112018000248A2 (pt) ?composto, composição, métodos de uma ou mais inibições da dutpase, para a reversão da resistência a uma terapia, para o tratamento de uma doença e para a inibição do crescimento de uma célula de câncer e conjunto?
BR112017021114A8 (pt) Compostos heterocíclicos como inibidores de lsd1